Login to Your Account

Spring Bank seeks to 'ACHIEVE' success with immunomodulator in HBV

By Marie Powers
News Editor

Wednesday, May 24, 2017

Reporting top-line data from the first phase IIa segment of its ACHIEVE study of SB-9200 in patients with chronic HBV, Spring Bank Pharmaceuticals Inc. suggested its lead candidate more than met its mark.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription